23
May
2018

Re-Starting a Company, Keeping Hope Alive: Chip Clark on The Long Run

Today’s guest on The Long Run is Chip Clark.

Chip Clark, CEO, Genocea 

He’s the CEO of Cambridge, Mass.-based Genocea Biosciences. This vaccine platform company got into a jam last summer. It completed a Phase II trial with its lead therapeutic vaccine for genital herpes. Clark tried to insist the trial was a success and the product had a future. The market disagreed. The stock tanked. Cash ran low. Morale ebbed.

Something had to be done.

How did Clark think about re-starting the company – pivoting, as he says – toward a new future as a personalized neoantigen cancer vaccine developer? Clark was pretty candid about this difficult stretch at Genocea, and I think many entrepreneurs will be able to relate to the experience and learn from it.

You may also like

Facing Up to a Political Crisis: BIO Chairman Jeremy Levin on The Long Run
The Cell Therapy Puzzle: Jane Grogan on The Long Run
Scientists at the Movies: Relay Therapeutics CEO Sanjiv Patel on The Long Run
A New Cholesterol-Lowering Drug at a Low Price: Tim Mayleben on The Long Run